Skip to main content
. 2016 Jul 22;33:97. doi: 10.1007/s12032-016-0811-3

Table 1.

Patient baseline characteristics (N = 121)

Group A (n = 59) n (%) Group B (n = 62) n (%) Total (n = 121) n (%)
Sex
 Male 23 (39) 15 (24) 38 (31)
 Female 36 (61) 47 (76) 83 (69)
Age (years)
 Median (range) 60 (30–86) 60 (33–80) 60 (30–86)
 <65 43 (73) 37 (60) 80
 ≥65 16 (27) 25 (4) 41
Smoking status
 Never 45 (76) 48 (78) 93 (77)
 Prior 10 (17) 12 (19) 22 (18)
 Current 4 (7) 2 (3) 6 (5)
ECOG PS
 0 5 (9) 4 (7) 9 (7)
 1 36 (61) 43 (69) 79 (65)
 2 18 (30) 15 (24) 33 (28)
EGFR mutation
 Exon 19 deletion 39 (66) 35 (57) 74 (61)
 Exon 21 L858R 20 (34) 27 (43) 47 (39)
EGFR TKI
 Gefitinib 54 (91) 49 (79) 103 (85)
 Erlotinib 5 (9) 13 (21) 18 (15)
Extracranial metastasis
 None 19 (32) 4 (7) 23 (19)
 One 18 (31) 28 (45) 46 (38)
 ≥Two 22 (37) 30 (48) 52 (43)
Site of extracranial metastasis
 Bone 28 (48) 40 (65) 68 (56)
 Lung 17 (29) 22 (36) 39 (32)
 Liver 10 (17) 10 (16) 20 (17)
 Pleura 6 (10) 17 (27) 23 (19)
 Adrenal gland 9 (15) 2 (3) 11 (9)
 Other 4 (7) 5 (8) 9 (7)
Number of BMs
 <5 21 (36) 15 (24) 36 (30)
 ≥5 38 (64) 47 (76) 85 (70)
Co-existing LMS
 Yes 10 (17) 10 (16) 20 (17)
 No 49 (83) 52 (84) 101 (93)
BM-related symptoms
 Yes 28 (48) 12 (20) 40 (33)
 No 31 (52) 50 (80) 81 (67)

ECOG PS Eastern Cooperative Oncology Group performance status, EGFR epidermal growth factor receptor, TKI tyrosine kinase inhibitor, BM brain metastasis, LMS leptomeningeal carcinomatosis